These questions are fast becoming critical for today's business leaders because the need to understand the implications of AI will dictate what changes to how a business and its people operate in anticipation of that are needed today. In every case, however, the answer is the same: educate yourself.
It's been a long-fought battle in the pharmaceutical industry. And now, consumer watchdog Which? has uncovered how some drugs firms are selling pain pills for 10 times the price of generic alternatives. It has never been a secret: it's just a matter of education.
Imagine the scenario: It's late at night and your partner wakes feeling desperately poorly with a headache. You run downstairs, check the cupboard, and realise that you're out of painkillers. Determined to help ease their suffering, you drive to the nearest shop, reach for the ibuprofen and take it to the till.
Our solution to this problem was to increase the number of languages and the number of pharmacies enrolled so that each pharmacy can give us fewer surveys and we can still hit data collection targets.
ASA said Nurofen Joint and Back doesn't specifically target back pain, like their advert suggested.
A Nurofen TV advert has been banned by the UK's advertising watchdog for misleading customers by telling them their pills
The new drug regulatory authority does present a case for hope, but if the systemic impediments and potential distortions and loopholes in the law are not addressed, it may lead to an even worse failure than what the earlier red-tape variant of drug regulation resulted in.
The commercial backdrop for any pharmaceutical company bringing a product to market is the changing market landscape they face. This is largely one of fragmentation, both in terms of the types of patient who are appropriate for targeting and in terms of the disease.
I was carving a loaf of bread this weekend, with my new bread knife. For some reason, I didn't look at the knife and think to myself, 'Wow, that's some knife skills you have, maybe you could be a surgeon'.
Pharmaceuticals giant AstraZeneca said today that it will axe 7,300 jobs by the end of 2014 as part of a fresh round of cost